AQR Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $250M | Buy |
1,338,458
+461,191
| +53% | +$80.6M | 0.11% | 242 |
|
|
2025
Q4 | $149M | Buy |
877,267
+178,326
| +26% | +$27.3M | 0.08% | 344 |
|
|
2025
Q3 | $91M | Sell |
698,941
-95,829
| -12% | -$11.5M | 0.06% | 438 |
|
|
2025
Q2 | $84.3M | Buy |
794,770
+304,463
| +62% | +$33.1M | 0.07% | 399 |
|
|
2025
Q1 | $59.8M | Sell |
490,307
-43,375
| -8% | -$5.66M | 0.06% | 409 |
|
|
2024
Q4 | $65.7M | Sell |
533,682
-19,883
| -4% | -$2.34M | 0.08% | 301 |
|
|
2024
Q3 | $61.4M | Sell |
553,565
-65,535
| -11% | -$7.18M | 0.08% | 315 |
|
|
2024
Q2 | $66.1M | Sell |
619,100
-125,546
| -17% | -$13.8M | 0.1% | 245 |
|
|
2024
Q1 | $89.7M | Buy |
744,646
+440,363
| +145% | +$53.9M | 0.15% | 160 |
|
|
2023
Q4 | $37.4M | Buy |
304,283
+125,172
| +70% | +$15.6M | 0.07% | 325 |
|
|
2023
Q3 | $23.2M | Buy |
179,111
+51,871
| +41% | +$6.91M | 0.05% | 433 |
|
|
2023
Q2 | $15.8M | Sell |
127,240
-25,218
| -17% | -$3.39M | 0.03% | 540 |
|
|
2023
Q1 | $22.1M | Buy |
152,458
+41,241
| +37% | +$6.1M | 0.05% | 439 |
|
|
2022
Q4 | $17.6M | Buy |
111,217
+79,010
| +245% | +$11.6M | 0.04% | 510 |
|
|
2022
Q3 | $4.29M | Buy |
+32,207
| New | +$4.9M | 0.01% | 886 |
|
|
2022
Q1 | – | Sell |
-151,827
| Closed | -$19.3M | – | 2251 |
|
|
2021
Q4 | $19.3M | Sell |
151,827
-325,496
| -68% | -$42.8M | 0.04% | 493 |
|
|
2021
Q3 | $62.2M | Sell |
477,323
-481,068
| -50% | -$72.7M | 0.12% | 210 |
|
|
2021
Q2 | $169M | Sell |
958,391
-114,969
| -11% | -$19.9M | 0.29% | 76 |
|
|
2021
Q1 | $176M | Buy |
1,073,360
+60,065
| +6% | +$9.88M | 0.29% | 73 |
|
|
2020
Q4 | $165M | Sell |
1,013,295
-290,936
| -22% | -$43.3M | 0.29% | 77 |
|
|
2020
Q3 | $184M | Sell |
1,304,231
-630,550
| -33% | -$78.2M | 0.31% | 66 |
|
|
2020
Q2 | $211M | Sell |
1,934,781
-419,046
| -18% | -$46.3M | 0.34% | 63 |
|
|
2020
Q1 | $235M | Buy |
2,353,827
+387,575
| +20% | +$50.1M | 0.39% | 51 |
|
|
2019
Q4 | $293M | Buy |
1,966,252
+633,022
| +47% | +$86.1M | 0.33% | 76 |
|
|
2019
Q3 | $169M | Buy |
1,333,230
+276,211
| +26% | +$37M | 0.2% | 134 |
|
|
2019
Q2 | $147M | Buy |
1,057,019
+337,396
| +47% | +$45.3M | 0.16% | 163 |
|
|
2019
Q1 | $102M | Buy |
719,623
+216,323
| +43% | +$28.2M | 0.11% | 223 |
|
|
2018
Q4 | $62.4M | Buy |
503,300
+158,987
| +46% | +$23.6M | 0.07% | 290 |
|
|
2018
Q3 | $57.9M | Buy |
344,313
+210,156
| +157% | +$36.1M | 0.06% | 346 |
|
|
2018
Q2 | $23.2M | Buy |
134,157
+13,948
| +12% | +$2.28M | 0.02% | 557 |
|
|
2018
Q1 | $18.1M | Buy |
120,209
+2,545
| +2% | +$373K | 0.02% | 613 |
|
|
2017
Q4 | $15.8M | Buy |
117,664
+89,601
| +319% | +$12.4M | 0.02% | 663 |
|
|
2017
Q3 | $4.1M | Sell |
28,063
-4,661
| -14% | -$705K | ﹤0.01% | 1097 |
|
|
2017
Q2 | $5.09M | Sell |
32,724
-126,367
| -79% | -$19.3M | 0.01% | 1014 |
|
|
2017
Q1 | $23.1M | Sell |
159,091
-190,321
| -54% | -$24.8M | 0.03% | 567 |
|
|
2016
Q4 | $38.1M | Buy |
349,412
+40,237
| +13% | +$4.48M | 0.05% | 445 |
|
|
2016
Q3 | $37.6M | Buy |
309,175
+276,790
| +855% | +$37.3M | 0.06% | 435 |
|
|
2016
Q2 | $4.58M | Buy |
32,385
+10,513
| +48% | +$1.55M | 0.01% | 950 |
|
|
2016
Q1 | $2.85M | Sell |
21,872
-11,049
| -34% | -$1.38M | 0.01% | 1090 |
|
|
2015
Q4 | $4.63M | Buy |
32,921
+13,417
| +69% | +$1.86M | 0.01% | 935 |
|
|
2015
Q3 | $2.59M | Buy |
19,504
+13,620
| +231% | +$2.35M | 0.01% | 1025 |
|
|
2015
Q2 | $1.04M | Sell |
5,884
-22
| -0.4% | -$3.95K | ﹤0.01% | 1475 |
|
|
2015
Q1 | $1.02M | Sell |
5,906
-11,500
| -66% | -$1.97M | ﹤0.01% | 1408 |
|
|
2014
Q4 | $2.85M | Buy |
+17,406
| New | +$2.89M | 0.01% | 1133 |
|
Other funds holding JAZZ
VPM
VCM
EC
AQR Capital Management's JAZZ Position: Q1 2026 in Review
AQR Capital Management increased its Jazz Pharmaceuticals (JAZZ) stake by 53% in Q1 2026, buying an estimated $80.6M and bringing the position to 1,338,458 shares worth $250M. The position accounts for 0.11% of the portfolio, ranked #242.
AQR Capital Management first reported a position in JAZZ in Q4 2014 and has held it in 44 quarters since. The position peaked at $293M in Q4 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- AQR Capital Management held 1,338,458 shares of Jazz Pharmaceuticals worth $250M as of Q1 2026.
- AQR Capital Management bought 461,191 Jazz Pharmaceuticals shares in Q1 2026, an estimated $80.6M.
- Jazz Pharmaceuticals made up 0.11% of AQR Capital Management's portfolio in Q1 2026, its #242 holding.
- AQR Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 44 quarters since.
- AQR Capital Management's Jazz Pharmaceuticals position peaked at $293M in Q4 2019.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.